ADPT

Adaptive Biotechnologies Corp

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1478320Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$277.0M

Net Income FY2025

$(59.0M)

EPS (Basic, as reported)

$-0.39

Net Margin FY2025

-21.5%

ROE FY2025

-27.2%

Total Equity

$219.0M

Shares Out

160M

Business description

Adaptive Biotechnologies Corp — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 38 → 277 +28.2% CAGR

Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue38568598154185170179277

Cost of revenue(16)(20)(22)(23)(49)(58)(76)(72)(71)

Research & development(32)(39)(71)(116)(142)(142)(122)(103)(94)

Selling & marketing(17)(24)(38)(61)(95)(96)(89)(85)(95)

General & administrative(16)(20)(30)(50)(75)(89)(84)(73)(73)

Total operating expenses(83)(105)(163)(251)(363)(385)(397)(342)(334)

Operating income(44)(50)(78)(153)(209)(200)(227)(163)(57)

Interest expense—————(4)(14)(12)(12)

Pre-tax income——(69)(146)(207)(200)(225)(160)(59)

Income tax expense——————000

Net income(43)(46)(69)(146)(207)(200)(225)(159)(59)

EPS — basic———($1.11)($1.48)($1.40)($1.56)($1.08)($0.39)

EPS — diluted———($1.11)($1.48)($1.40)($1.56)($1.08)($0.39)

Shares outstanding — basic (M)———131140143144147152

Shares outstanding — diluted (M)———131140143144147152

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.